Table 2. Incident HIV-1 infections detected during Phambili and Phambili + HVTN 503-S follow-up periods.
| Overall | Vaccine | Placebo | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Person-years | N | # infections | Annualized HIV-1 incidence rate | (95% CI) | N | # infections | Annualized HIV-1 incidence rate | (95% CI) | |
| Phambili follow-up | |||||||||
| All | 2269 | 400 | 63 | 5.6% | (4.3, 7.2) | 400 | 37 | 3.2% | (2.3, 4.5) |
| Men | 1269 | 222 | 28 | 4.4% | (2.9, 6.4) | 219 | 11 | 1.7% | (0.9, 3.1) |
| Women | 1000 | 178 | 35 | 7.2% | (5.0, 10.0) | 181 | 26 | 5.1% | (3.3, 7.4) |
| Phambili + 503-S follow-up | |||||||||
| All | 3555 | 400 | 82 | 4.7% | (3.7, 5.8) | 400 | 54 | 3.0% | (2.3, 3.9) |
| Men | 1998 | 222 | 39 | 3.9% | (2.8, 5.3) | 219 | 14 | 1.4% | (0.8, 2.3) |
| Women | 1557 | 178 | 43 | 5.6% | (4.1, 7.6) | 181 | 40 | 5.0% | (3.6, 6.9) |
| Completed Phambili FU | 2968 | 312 | 75 | 5.1% | (4.0, 6.4) | 299 | 50 | 3.4% | (2.5, 4.4) |
| Discontinued Phambili FU | 586 | 88 | 7 | 2.5% | (1.0, 5.1) | 101 | 4 | 1.3% | (0.4, 3.4) |
| Men completed Phambili FU | 1605 | 167 | 33 | 4.0% | (2.8, 5.7) | 150 | 14 | 1.8% | (1.0, 3.0) |
| Women completed Phambili FU | 1363 | 145 | 42 | 6.4% | (4.6, 8.6) | 149 | 36 | 5.1% | (3.6, 7.1) |
| Men discontinued Phambili FU | 393 | 55 | 6 | 3.4% | (1.2, 7.3) | 69 | 0 | 0.0% | 0.0, 1.7) |
| Women discontinued Phambili FU | 193 | 33 | 1 | 1.0% | (0.0, 5.4) | 32 | 4 | 4.5% | (1.2,11.4) |
CI = confidence interval. HIV-1 = human immunodeficiency virus 1.